Condition
Meningococcal
Total Trials
4
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
75%
3 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
P 1 (1)
P 3 (2)
P 4 (1)
Trial Status
Completed2
Recruiting1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06834100Phase 3Recruiting
Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison With the Reference Drug
NCT03746665Phase 3Unknown
Maternal Immunization With MenAfriVac™
NCT02072525Phase 4CompletedPrimary
A Protocol to Collect Human Serum Samples From Healthy Adults for Use as Quality Controls Samples in GlaxoSmithKline (GSK) Biologicals' Assays
NCT02867319Phase 1CompletedPrimary
Safety Study of ACYW135 Meningococcal Polysaccharide Vaccine Aged 2-50 Years Old
Showing all 4 trials